Compared with standard chemotherapy, the PARP inhibitor extended progression-free survival for patients with advanced BCRA-positive breast cancer.
FDA Approvals …read more
Compared with standard chemotherapy, the PARP inhibitor extended progression-free survival for patients with advanced BCRA-positive breast cancer.
FDA Approvals …read more
Comments are closed.
Nice posts! 🙂
___
Sanny